Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET
Company Participants
McDavid Stilwell - CFO
Denny Lanfear - President, CEO, and Chairman
Paul Reider - CCO
Theresa LaVallee - CDO
Conference Call Participants
Balaji Prasad - Barclays
Jason Gerberry - Bank of America
Georgi Yordanov - Cowen and Company
Operator
Good day, and thank you for standing by. Welcome to the Coherus Biosciences Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to your speaker today, McDavid Stilwell, Chief Financial Officer. Please go ahead, sir.
McDavid Stilwell
Thank you, operator. Good afternoon, everyone, and thank you for joining us. We issued our press release earlier announcing our financial results for the first quarter of 2022. The results can be found -- the release can be found on the Coherus BioSciences' website.
Today's call includes forward-looking statements regarding Coherus' current expectations about future events. These statements include, but are not limited to, our ability to advance our product candidates through development and registration, the status of product candidate clinical profile, our timing and ability to commercialization our products and product candidates in the future, our R&D and SG&A expense guidance for 2022, our revenue targets for 2026, and our ability to meet the same; our projections about margin as well as our ability to drive down amounts under our new credit facility, and the timing of the resubmission and review of the toripalimab BLA. All these future events involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance or achievement to differ from the results, performance or achievement implied by the forward-looking statements.
These statements are not guarantees of future performance and are subject to substantial risks and uncertainties that are discussed in our press release that we issued today, as well as in the document that we file with the Securities and Exchange Commission, including those in our quarterly on Form 10-Q with today's date. The forward-looking statements provided on the call today are made as of this date and we undertake no duty to update or revise any forward-looking statements.
With me on today's call are Denny Lanfear, CEO of Coherus; Paul Reider, Chief Commercial Officer; Theresa LaVallee, Chief Development Officer; and Dr. Rosh Dias, Chief Medical Officer.